Hikma Pharmaceuticals Share News (HIK)

REPEAT: Hikma Pharma Raises 2013 Revenue Guidance After Strong End To Year

LONDON (Alliance News) - Hikma Pharmaceuticals PLC Friday raised its revenue growth forecasts for 2013, saying its injectables and generics businesses performed strongly towards the end of the year, although it cautioned that generics revenues will likely be lower in 2014. In a trading stat

UK MORNING BRIEFING: Shares Mixed; Anglo American Swings To Profit

LONDON (Alliance News) - Shares have opened mixed in London Friday, with blue-chips lagging mid- and small-caps despite Anglo American and Coca Cola HBC both reporting swings to profit in 2013. Anglo American is up 1.7% at the open, while Coca Cola HBC is down

Hikma Pharmaceuticals to deliver higher than expected FY revenue

Hikma Pharmaceuticals on Friday reported a strong performance by its Injectables business ahead of the release of its 2013 results next month, which it said would now show a higher-than-expected revenue increase. The group said revenue for the 12-month period would now be around 23% above the prior

Hikma Pharma Raises 2013 Revenue Guidance After Strong End To Year

LONDON (Alliance News) - Hikma Pharmaceuticals PLC Friday raised its revenue growth forecasts for 2013, saying its injectables and generics businesses performed strongly towards the end of the year, although it cautioned that generics revenues will likely be lower in 2014. In a trading stat

Hikma estimates 23 percent full-year revenue growth

Feb 14 (Reuters) - Hikma Pharmaceuticals Plc said it expects a 23 percent growth in full-year revenue, up from its prior forecast of about 20 percent, benefiting from strong performance in its injectables and generics businesses towards the end of 2013. The company, which has grown over the

UK BROKER RATINGS: Goldman Sachs Initiates Vodafone With Buy Rating

LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:
----------
FTSE 100
----------
GOLDMAN STARTS VODAFONE WITH 'BUY' - PRICE TARGET 275 PENCE
----------
MORGAN STANLEY RAISES ASTRAZENECA PRICE TARGET

UK BROKER RATINGS: Credit Suisse Raises Reckitt To Outperform

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning and Wednesday afternoon:
----------
FTSE 100
----------
S&P CAPITAL IQ CUTS BG GROUP PRICE TARGET TO 1050 (1063) PENCE - 'SELL'
----------
CRED

UK MORNING BRIEFING: Vodafone Gains, AstraZeneca Falls At Open

LONDON (Alliance News) - Vodafone has delivered results in line with expectations Thursday morning, helping to give UK share a positive start. Vodafone is up 1.4%.

Meanwhile, AstraZeneca has opened down 2.1% after reporting lower revenue and profit

UK MORNING BRIEFING:

LONDON (Alliance News) - Vodafone has delivered results in line with expectations Thursday morning, helping to give UK share a positive start. Vodafone is up 1.4%.

Meanwhile, AstraZeneca has opened down 2.1% after reporting lower revenue and profit

UK BROKER RATING CHANGES: Barclays Raises Schroders to Overweight

MARKET COMMENT: UK Stocks Close Mixed For First Session Of 2014

UK WINNERS & LOSERS: Hikma Jumps On UBS Upgrade

STOCKS NEWS EUROPE- Hikma shares rise on UBS upgrade

Shares in Hikma Pharmaceuticals Plc rise 4 percent after UBS upgrades the company's stock to "buy" from "neutral", as it expects the drugmaker to benefit from a weaker Japanese yen and to continue to profit from sales of doxycycline - an antibiotic to treat malaria. The brokerage said that,

DIRECTOR DEALINGS: Hikma Pharma Director Commits Shares To Loan

UK BROKER RATING CHANGES: Brokers Raise View On Mitchell & Butlers